Revance Reports Fourth Quarter and Full Year 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Revance Therapeutics (RVNC) Reports In-Line Q4 EPS, Revenues Beat
February 22, 2021 4:41 PM ESTRevance Therapeutics (NASDAQ: RVNC) reported Q4 EPS of ($1.24), in-line with the analyst estimate of ($1.24). Revenue for the quarter came in at $11.13 million versus the consensus estimate of $8.78 million.
Fourth quarter and full year 2020 total product and service revenue of $10.2 million and $13.3 million, respectivelyFirst full quarter of RHA® Collection of dermal fillers revenue of $10.0 millionExited 2020 with over $200 million in annualized HintMD processing volumeCash, cash equivalents and short-term investments balance of $436.5 million at... More